Does the media prefer WST or BLCO?

In the previous week, West Pharmaceutical Services had 7 more articles in the media than Bausch + Lomb. MarketBeat recorded 15 mentions for West Pharmaceutical Services and 8 mentions for Bausch + Lomb. West Pharmaceutical Services' average media sentiment score of 0.88 beat Bausch + Lomb's score of 0.33 indicating that West Pharmaceutical Services is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment West Pharmaceutical Services 9 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bausch + Lomb 1 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, BLCO or SOLV?

Solventum has higher revenue and earnings than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than Solventum, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bausch + Lomb $5.32B 1.16 -$360M -$0.48 N/A Solventum $8.33B 1.79 $1.56B $8.18 10.69

Is BLCO or SOLV more profitable?

Solventum has a net margin of 17.26% compared to Bausch + Lomb's net margin of -3.21%. Solventum's return on equity of 25.09% beat Bausch + Lomb's return on equity. Company Net Margins Return on Equity Return on Assets Bausch + Lomb -3.21% 4.14% 1.93% Solventum 17.26% 25.09% 8.78%

Does the media favor BLCO or SOLV?

In the previous week, Bausch + Lomb had 1 more articles in the media than Solventum. MarketBeat recorded 8 mentions for Bausch + Lomb and 7 mentions for Solventum. Solventum's average media sentiment score of 1.34 beat Bausch + Lomb's score of 0.33 indicating that Solventum is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bausch + Lomb 1 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Solventum 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor BLCO or COO?

In the previous week, Cooper Companies had 68 more articles in the media than Bausch + Lomb. MarketBeat recorded 76 mentions for Cooper Companies and 8 mentions for Bausch + Lomb. Bausch + Lomb's average media sentiment score of 0.33 beat Cooper Companies' score of 0.21 indicating that Bausch + Lomb is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bausch + Lomb 1 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cooper Companies 16 Very Positive mention(s) 7 Positive mention(s) 20 Neutral mention(s) 16 Negative mention(s) 6 Very Negative mention(s) Neutral

Does the media favor BLCO or ALGN?

In the previous week, Align Technology had 5 more articles in the media than Bausch + Lomb. MarketBeat recorded 13 mentions for Align Technology and 8 mentions for Bausch + Lomb. Align Technology's average media sentiment score of 1.23 beat Bausch + Lomb's score of 0.33 indicating that Align Technology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bausch + Lomb 1 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Align Technology 10 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor BLCO or MMSI?

In the previous week, Bausch + Lomb had 4 more articles in the media than Merit Medical Systems. MarketBeat recorded 8 mentions for Bausch + Lomb and 4 mentions for Merit Medical Systems. Merit Medical Systems' average media sentiment score of 1.56 beat Bausch + Lomb's score of 0.33 indicating that Merit Medical Systems is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bausch + Lomb 1 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Merit Medical Systems 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Bausch + Lomb (BLCO) Competitors

$17.26 -0.29 (-1.66%)

Closing price 09/11/2026 03:58 PM Eastern

Extended Trading

$17.13 -0.13 (-0.76%)

As of 09/11/2026 07:30 PM Eastern

Compare

BLCO vs. WST, SOLV, COO, ALGN, and MMSI

Should you buy Bausch + Lomb stock or one of its competitors? Bausch + Lomb's main competitors and comparable companies include West Pharmaceutical Services (WST), Solventum (SOLV), Cooper Companies (COO), Align Technology (ALGN), and Merit Medical Systems (MMSI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare supplies" industry.

How does Bausch + Lomb compare to West Pharmaceutical Services?

West Pharmaceutical Services (NYSE:WST) and Bausch + Lomb (NYSE:BLCO) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, media sentiment, valuation, dividends and profitability.

93.9% of West Pharmaceutical Services shares are held by institutional investors. Comparatively, 11.1% of Bausch + Lomb shares are held by institutional investors. 0.6% of West Pharmaceutical Services shares are held by insiders. Comparatively, 1.5% of Bausch + Lomb shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

West Pharmaceutical Services has a beta of 1.14, meaning that its stock price is 14% more volatile than the broader market. Comparatively, Bausch + Lomb has a beta of 0.56, meaning that its stock price is 44% less volatile than the broader market.

West Pharmaceutical Services has a net margin of 16.98% compared to Bausch + Lomb's net margin of -3.21%. West Pharmaceutical Services' return on equity of 20.11% beat Bausch + Lomb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
West Pharmaceutical Services	16.98%	20.11%	14.83%
Bausch + Lomb	-3.21%	4.14%	1.93%

In the previous week, West Pharmaceutical Services had 7 more articles in the media than Bausch + Lomb. MarketBeat recorded 15 mentions for West Pharmaceutical Services and 8 mentions for Bausch + Lomb. West Pharmaceutical Services' average media sentiment score of 0.88 beat Bausch + Lomb's score of 0.33 indicating that West Pharmaceutical Services is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
West Pharmaceutical Services	9 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bausch + Lomb	1 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

West Pharmaceutical Services presently has a consensus price target of $373.85, suggesting a potential upside of 8.21%. Bausch + Lomb has a consensus price target of $19.15, suggesting a potential upside of 10.99%. Given Bausch + Lomb's higher possible upside, analysts clearly believe Bausch + Lomb is more favorable than West Pharmaceutical Services.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
West Pharmaceutical Services	0 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.87
Bausch + Lomb	1 Sell rating(s)	7 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.36

West Pharmaceutical Services has higher earnings, but lower revenue than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than West Pharmaceutical Services, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
West Pharmaceutical Services	$3.33B	7.31	$493.70M	$7.81	44.24
Bausch + Lomb	$5.32B	1.16	-$360M	-$0.48	N/A

Summary

West Pharmaceutical Services beats Bausch + Lomb on 14 of the 17 factors compared between the two stocks.

How does Bausch + Lomb compare to Solventum?

Bausch + Lomb (NYSE:BLCO) and Solventum (NYSE:SOLV) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, media sentiment, profitability and dividends.

In the previous week, Bausch + Lomb had 1 more articles in the media than Solventum. MarketBeat recorded 8 mentions for Bausch + Lomb and 7 mentions for Solventum. Solventum's average media sentiment score of 1.34 beat Bausch + Lomb's score of 0.33 indicating that Solventum is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bausch + Lomb	1 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Solventum	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

11.1% of Bausch + Lomb shares are held by institutional investors. 1.5% of Bausch + Lomb shares are held by company insiders. Comparatively, 0.2% of Solventum shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Solventum has a net margin of 17.26% compared to Bausch + Lomb's net margin of -3.21%. Solventum's return on equity of 25.09% beat Bausch + Lomb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch + Lomb	-3.21%	4.14%	1.93%
Solventum	17.26%	25.09%	8.78%

Bausch + Lomb currently has a consensus price target of $19.15, suggesting a potential upside of 10.99%. Solventum has a consensus price target of $92.80, suggesting a potential upside of 6.15%. Given Bausch + Lomb's higher possible upside, research analysts clearly believe Bausch + Lomb is more favorable than Solventum.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch + Lomb	1 Sell rating(s)	7 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.36
Solventum	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58

Solventum has higher revenue and earnings than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than Solventum, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch + Lomb	$5.32B	1.16	-$360M	-$0.48	N/A
Solventum	$8.33B	1.79	$1.56B	$8.18	10.69

Bausch + Lomb has a beta of 0.56, meaning that its share price is 44% less volatile than the broader market. Comparatively, Solventum has a beta of 0.61, meaning that its share price is 39% less volatile than the broader market.

Summary

Solventum beats Bausch + Lomb on 12 of the 16 factors compared between the two stocks.

How does Bausch + Lomb compare to Cooper Companies?

Bausch + Lomb (NYSE:BLCO) and Cooper Companies (NASDAQ:COO) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, media sentiment, analyst recommendations, dividends and profitability.

In the previous week, Cooper Companies had 68 more articles in the media than Bausch + Lomb. MarketBeat recorded 76 mentions for Cooper Companies and 8 mentions for Bausch + Lomb. Bausch + Lomb's average media sentiment score of 0.33 beat Cooper Companies' score of 0.21 indicating that Bausch + Lomb is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bausch + Lomb	1 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cooper Companies	16 Very Positive mention(s)	7 Positive mention(s)	20 Neutral mention(s)	16 Negative mention(s)	6 Very Negative mention(s)	Neutral

Bausch + Lomb has a beta of 0.56, suggesting that its stock price is 44% less volatile than the broader market. Comparatively, Cooper Companies has a beta of 0.82, suggesting that its stock price is 18% less volatile than the broader market.

Cooper Companies has lower revenue, but higher earnings than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than Cooper Companies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch + Lomb	$5.32B	1.16	-$360M	-$0.48	N/A
Cooper Companies	$4.24B	2.48	$374.90M	$2.93	18.40

11.1% of Bausch + Lomb shares are held by institutional investors. Comparatively, 24.4% of Cooper Companies shares are held by institutional investors. 1.5% of Bausch + Lomb shares are held by company insiders. Comparatively, 2.1% of Cooper Companies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Bausch + Lomb presently has a consensus price target of $19.15, indicating a potential upside of 10.99%. Cooper Companies has a consensus price target of $71.47, indicating a potential upside of 32.57%. Given Cooper Companies' higher possible upside, analysts clearly believe Cooper Companies is more favorable than Bausch + Lomb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch + Lomb	1 Sell rating(s)	7 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.36
Cooper Companies	2 Sell rating(s)	11 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.17

Cooper Companies has a net margin of 13.46% compared to Bausch + Lomb's net margin of -3.21%. Cooper Companies' return on equity of 10.90% beat Bausch + Lomb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch + Lomb	-3.21%	4.14%	1.93%
Cooper Companies	13.46%	10.90%	7.24%

Summary

Cooper Companies beats Bausch + Lomb on 12 of the 16 factors compared between the two stocks.

How does Bausch + Lomb compare to Align Technology?

Bausch + Lomb (NYSE:BLCO) and Align Technology (NASDAQ:ALGN) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, valuation, profitability, media sentiment, analyst recommendations, earnings, institutional ownership and dividends.

11.1% of Bausch + Lomb shares are owned by institutional investors. Comparatively, 88.4% of Align Technology shares are owned by institutional investors. 1.5% of Bausch + Lomb shares are owned by company insiders. Comparatively, 0.8% of Align Technology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Bausch + Lomb currently has a consensus target price of $19.15, suggesting a potential upside of 10.99%. Align Technology has a consensus target price of $206.36, suggesting a potential upside of 36.82%. Given Align Technology's stronger consensus rating and higher possible upside, analysts clearly believe Align Technology is more favorable than Bausch + Lomb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch + Lomb	1 Sell rating(s)	7 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.36
Align Technology	0 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.67

Align Technology has lower revenue, but higher earnings than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than Align Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch + Lomb	$5.32B	1.16	-$360M	-$0.48	N/A
Align Technology	$4.14B	2.61	$410.35M	$5.75	26.23

Align Technology has a net margin of 9.99% compared to Bausch + Lomb's net margin of -3.21%. Align Technology's return on equity of 15.86% beat Bausch + Lomb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch + Lomb	-3.21%	4.14%	1.93%
Align Technology	9.99%	15.86%	10.32%

In the previous week, Align Technology had 5 more articles in the media than Bausch + Lomb. MarketBeat recorded 13 mentions for Align Technology and 8 mentions for Bausch + Lomb. Align Technology's average media sentiment score of 1.23 beat Bausch + Lomb's score of 0.33 indicating that Align Technology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bausch + Lomb	1 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Align Technology	10 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Bausch + Lomb has a beta of 0.56, meaning that its stock price is 44% less volatile than the broader market. Comparatively, Align Technology has a beta of 1.65, meaning that its stock price is 65% more volatile than the broader market.

Summary

Align Technology beats Bausch + Lomb on 15 of the 17 factors compared between the two stocks.

How does Bausch + Lomb compare to Merit Medical Systems?

Bausch + Lomb (NYSE:BLCO) and Merit Medical Systems (NASDAQ:MMSI) are both mid-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, media sentiment, risk and dividends.

11.1% of Bausch + Lomb shares are owned by institutional investors. Comparatively, 99.7% of Merit Medical Systems shares are owned by institutional investors. 1.5% of Bausch + Lomb shares are owned by company insiders. Comparatively, 0.7% of Merit Medical Systems shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Bausch + Lomb has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market. Comparatively, Merit Medical Systems has a beta of 0.49, indicating that its stock price is 51% less volatile than the broader market.

In the previous week, Bausch + Lomb had 4 more articles in the media than Merit Medical Systems. MarketBeat recorded 8 mentions for Bausch + Lomb and 4 mentions for Merit Medical Systems. Merit Medical Systems' average media sentiment score of 1.56 beat Bausch + Lomb's score of 0.33 indicating that Merit Medical Systems is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bausch + Lomb	1 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Merit Medical Systems	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Merit Medical Systems has a net margin of 9.22% compared to Bausch + Lomb's net margin of -3.21%. Merit Medical Systems' return on equity of 13.75% beat Bausch + Lomb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch + Lomb	-3.21%	4.14%	1.93%
Merit Medical Systems	9.22%	13.75%	8.10%

Merit Medical Systems has lower revenue, but higher earnings than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than Merit Medical Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch + Lomb	$5.32B	1.16	-$360M	-$0.48	N/A
Merit Medical Systems	$1.52B	3.40	$128.49M	$2.42	35.69

Bausch + Lomb presently has a consensus target price of $19.15, indicating a potential upside of 10.99%. Merit Medical Systems has a consensus target price of $100.00, indicating a potential upside of 15.79%. Given Merit Medical Systems' stronger consensus rating and higher probable upside, analysts plainly believe Merit Medical Systems is more favorable than Bausch + Lomb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch + Lomb	1 Sell rating(s)	7 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.36
Merit Medical Systems	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.83

Summary

Merit Medical Systems beats Bausch + Lomb on 13 of the 17 factors compared between the two stocks.

Get Bausch + Lomb News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BLCO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BLCO vs. The Competition

Export

Metric	Bausch + Lomb	Healthcare Equipment & Supplies Industry	Healthcare Sector	NYSE Exchange
Market Cap	$6.27B	$5.44B	$7.15B	$23.18B
Dividend Yield	N/A	1.79%	2.56%	3.56%
P/E Ratio	-35.95	25.09	274.95	28.71
Price / Sales	1.16	82.90	656.56	94.44
Price / Cash	10.52	32.53	77.04	33.82
Price / Book	0.94	5.97	10.33	4.74
Net Income	-$360M	$150.75M	$3.50B	$1.07B
7 Day Performance	-4.28%	-2.83%	-3.32%	-2.00%
1 Month Performance	2.67%	-3.09%	-0.41%	-2.69%
1 Year Performance	13.43%	9.34%	19.21%	10.45%

Bausch + Lomb Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BLCO Bausch + Lomb	3.7771 of 5 stars	$17.26 -1.7%	$19.15 +11.0%	+12.7%	$6.27B	$5.32B	N/A	13,000	News Coverage Analyst Forecast
WST West Pharmaceutical Services	3.6606 of 5 stars	$339.90 -0.8%	$368.08 +8.3%	+31.1%	$23.93B	$3.07B	43.52	10,800	Analyst Forecast Insider Trade
SOLV Solventum	2.0086 of 5 stars	$91.70 -0.8%	$91.64 -0.1%	+18.6%	$15.61B	$8.33B	11.21	20,000	News Coverage Positive News Analyst Upgrade
COO Cooper Companies	3.9297 of 5 stars	$69.59 -1.5%	$81.64 +17.3%	-21.3%	$13.57B	$4.09B	58.97	15,000	Trending News Earnings Report Analyst Forecast Buyback Announcement
ALGN Align Technology	3.9658 of 5 stars	$158.63 -0.8%	$206.36 +30.1%	+11.0%	$11.36B	$4.03B	27.59	20,290	Positive News Options Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:BLCO) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bausch + Lomb (BLCO) Competitors

BLCO vs. WST, SOLV, COO, ALGN, and MMSI

How does Bausch + Lomb compare to West Pharmaceutical Services?

Summary

How does Bausch + Lomb compare to Solventum?

Summary

How does Bausch + Lomb compare to Cooper Companies?

Summary

How does Bausch + Lomb compare to Align Technology?

Summary

How does Bausch + Lomb compare to Merit Medical Systems?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BLCO vs. The Competition

Bausch + Lomb Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bausch + Lomb (BLCO) Competitors

BLCO vs. WST, SOLV, COO, ALGN, and MMSI

How does Bausch + Lomb compare to West Pharmaceutical Services?

Do institutionals & insiders hold more shares of WST or BLCO?

Which has more volatility & risk, WST or BLCO?

Is WST or BLCO more profitable?

Does the media prefer WST or BLCO?

Do analysts recommend WST or BLCO?

Which has better valuation & earnings, WST or BLCO?

Summary

How does Bausch + Lomb compare to Solventum?

Does the media favor BLCO or SOLV?

Do insiders and institutionals believe in BLCO or SOLV?

Is BLCO or SOLV more profitable?

Do analysts prefer BLCO or SOLV?

Which has preferable valuation and earnings, BLCO or SOLV?

Which has more risk & volatility, BLCO or SOLV?

Summary

How does Bausch + Lomb compare to Cooper Companies?

Does the media favor BLCO or COO?

Which has more volatility and risk, BLCO or COO?

Which has stronger valuation and earnings, BLCO or COO?

Do institutionals & insiders have more ownership in BLCO or COO?

Do analysts rate BLCO or COO?

Is BLCO or COO more profitable?

Summary

How does Bausch + Lomb compare to Align Technology?

Do institutionals & insiders hold more shares of BLCO or ALGN?

Do analysts prefer BLCO or ALGN?

Which has higher valuation & earnings, BLCO or ALGN?

Is BLCO or ALGN more profitable?

Does the media favor BLCO or ALGN?

Which has more volatility & risk, BLCO or ALGN?

Summary

How does Bausch + Lomb compare to Merit Medical Systems?

Do institutionals and insiders believe in BLCO or MMSI?

Which has more risk & volatility, BLCO or MMSI?

Does the media favor BLCO or MMSI?

Is BLCO or MMSI more profitable?

Which has better valuation & earnings, BLCO or MMSI?

Do analysts recommend BLCO or MMSI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BLCO vs. The Competition

Bausch + Lomb Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools